Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Alliance Pharma expects no profit growth in 2024

(Sharecast News) - Consumer healthcare group Alliance Pharma has said that 2023 results will be in line with market expectations but said that profits are unlikely to grow this year due to increased investment in sales and marketing. Consensus estimates for underlying profits in 2023 currently stand at £45m, up from £30m in 2022, but were expected to rise to £50m in 2024.

The company said it delivered record revenues of £182.7m last year, up 6% on 2022, with strong consumer demand in the second half, particularly in China. Free cash flow was up 34% at £21.1m while net debt reduced to £92.4m from £102m.

"Our portfolio continues to provide a robust platform from which to grow our Consumer Healthcare brands. In 2023, we delivered record revenues as we launched new advertising campaigns to accelerate organic sales growth whilst bringing new, innovative, products to market," said chief executive Peter Butterfield. "Our global ecommerce business is building strongly, as we entered several new, high growth geographies in 2023, and look to enter more this year."

However, in order to achieve medium-term objectives, the company said it would raise investment in sales and marketing, both directly and through its distributors. "The company will also continue to deliver innovation in 2024 to further expand the reach of its brands. As a result, the board anticipates that profits in 2024 will be in-line with 2023."

The stock was down 2.2% at 37.65p by 1116 GMT.

Share this article

Related Sharecast Articles

Checkit secures three contract wins, launches new product
(Sharecast News) - Software solutions firm Checkit said on Monday that it has secured new contract wins from two existing customers worth a minimum of £417,000 in total lifetime revenues over their three-year terms.
CyanConnode gets big order from IntelliSmart
(Sharecast News) - Narrowband radiofrequency and smart mesh network technology specialist CyanConnode announced receiving an order for 265,331 Omnimesh modules from Madhyanchal One Infrastructure on Monday, a subsidiary of IntelliSmart Infrastructure.
Getech secures three separate contract wins
(Sharecast News) - Subsurface resources locator Getech said on Monday that it had secured three separate contract wins related to the exploration of natural hydrogen.
Getech secures three separate contract wins
(Sharecast News) - Subsurface resources locator Getech said on Monday that it had secured three separate contract wins related to the exploration of natural hydrogen.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.